 , Agents Causing Muscle Toxicity , Anticholesteremic Agents , BSEP/ABCB11 Substrates , Cytochrome P-450 CYP2C19 Substrates , Cytochrome P-450 CYP2C8 Inhibitors , Cytochrome P-450 CYP2C8 Inhibitors (moderate) , Cytochrome P-450 CYP2C8 Substrates , Cytochrome P-450 CYP2C9 Inhibitors , Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) , Cytochrome P-450 CYP2D6 Inhibitors , Cytochrome P-450 CYP2D6 Inhibitors (weak) , Cytochrome P-450 CYP3A Inhibitors , Cytochrome P-450 CYP3A Substrates , Cytochrome P-450 CYP3A4 Inhibitors , Cytochrome P-450 CYP3A4 Inhibitors (moderate) , Cytochrome P-450 CYP3A4 Substrates , Cytochrome P-450 CYP3A5 Substrates , Cytochrome P-450 CYP3A7 Substrates , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Substrates , Drugs causing inadvertant photosensitivity , Enzyme Inhibitors , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Hypolipidemic Agents , Hypolipidemic Agents Indicated for Hyperlipidemia , Lipid Modifying Agents , Lipid Regulating Agents , OATP1B1/SLCO1B1 Inhibitors , OATP1B1/SLCO1B1 Substrates , P-glycoprotein inhibitors , Photosensitizing Agents , UGT1A1 Substrates , UGT1A3 substrates , UGT2B7 substrates